In the Green: Biocryst Pharmaceuticals Inc. (BCRX) Closes at 6.74, Up/Down -0.74 from Previous Day

In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

In the latest session, Biocryst Pharmaceuticals Inc. (NASDAQ: BCRX) closed at $6.74 down -0.74% from its previous closing price of $6.79. In other words, the price has decreased by -$0.74 from its previous closing price. On the day, 2.68 million shares were traded. BCRX stock price reached its highest trading level at $6.8994 during the session, while it also had its lowest trading level at $6.665.

Ratios:

For a deeper understanding of Biocryst Pharmaceuticals Inc.’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.48 and its Current Ratio is at 3.73.

On September 18, 2023, RBC Capital Mkts Upgraded its rating to Outperform which previously was Sector Perform and also upped its target price recommendation from $9 to $10.

Jefferies Upgraded its Hold to Buy on August 04, 2023, while the target price for the stock was maintained at $11.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on May 30 ’24 when LEVIN ALAN G bought 7,861 shares for $6.36 per share. The transaction valued at 49,996 led to the insider holds 44,951 shares of the business.

ASELAGE STEVE bought 2,500 shares of BCRX for $16,000 on May 24 ’24. The Director now owns 2,500 shares after completing the transaction at $6.40 per share. On May 20 ’24, another insider, MILANO VINCENT, who serves as the Director of the company, bought 15,000 shares for $6.25 each. As a result, the insider paid 93,750 and bolstered with 66,997 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BCRX now has a Market Capitalization of 1390980864 and an Enterprise Value of 1907327616. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.91. Its current Enterprise Value per Revenue stands at 5.367 whereas that against EBITDA is -23.236.

Stock Price History:

Over the past 52 weeks, BCRX has reached a high of $8.96, while it has fallen to a 52-week low of $4.03. The 50-Day Moving Average of the stock is 30.01%, while the 200-Day Moving Average is calculated to be 15.80%.

Shares Statistics:

For the past three months, BCRX has traded an average of 3.64M shares per day and 3498230 over the past ten days. A total of 205.77M shares are outstanding, with a floating share count of 198.12M. Insiders hold about 4.00% of the company’s shares, while institutions hold 86.62% stake in the company. Shares short for BCRX as of 1715731200 were 34352068 with a Short Ratio of 9.45, compared to 1713139200 on 34385237. Therefore, it implies a Short% of Shares Outstanding of 34352068 and a Short% of Float of 16.780001.

Most Popular